Indi Molecular

OverviewSuggest Edit

PCCs were created in collaboration with the California Institute of Technology using “click chemistry,” a synthetic process that allows scientists to permanently join (“click”) together molecular components with remarkable precision and stability. PCCs offer the promise of improved selectivity, superior binding affinity, fully synthetic composition and a vastly low molecular weight compared to monoclonal antibodies, the current standard for identifying biomarkers in most diagnostics platforms – and in many therapeutic uses. The company launched as a spinout from its parent company Integrated Diagnostics (Indi) in 2013 with a $1.5 million seed round led by InterWest Partners together with several angel investors.
TypePrivate
Founded2013
HQCulver City, CA, US
Websiteindimolecular.com
Overall CultureA+

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2019)30
Cybersecurity ratingAMore

Key People/Management at Indi Molecular

Albert A. Luderer

Albert A. Luderer

CEO, Co-Founder & Board Member
Heather Agnew

Heather Agnew

Vice President R&D Operations
Michael T. Klimas

Michael T. Klimas

Senior Vice President of Strategy & Technical Business Development
Show more

Indi Molecular Office Locations

Indi Molecular has an office in Culver City
Culver City, CA, US (HQ)
6162 Bristol Pkwy
Show all (1)

Indi Molecular Financials and Metrics

Summary Metrics

Founding Date

2013

Indi Molecular total Funding

$11.5 m

Indi Molecular latest funding size

$11.5 m

Time since last funding

4 years ago

Indi Molecular investors

Indi Molecular's latest funding round in June 2017 was reported to be $11.5 m. In total, Indi Molecular has raised $11.5 m
Show all financial metrics

Indi Molecular Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Indi Molecular Online and Social Media Presence

Embed Graph

Indi Molecular Company Culture

  • Overall Culture

    A+

    93/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Indi Molecular News and Updates

Indi Molecular bags $11.5 mln

Indi Molecular, an emerging life sciences company, has raised $11.5 million in financing. The investors included M Ventures, Legend Capital, Sabey Corporation and Asset Management Ventures. In addition to the funding, Dr. Andreas Jurgeit from Merck Ventures and Dr. Darren Cai from Legend Capital wil…

Indi Molecular Blogs

CEO Q&A: Ovarian Cancer Target

We can build molecules that are small, able to carry a payload and that are highly specific in their binding ability.

Anglonordic Life Science Conference to Include Presentation by Indi Molecular CEO Albert A. Luderer

Indi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at the Anglonordic Life Science Conference held virtually May 25 - 28, 2021.

Indi Molecular CEO Albert A. Luderer to Present at Spring 2021 Oncology Investor Conference on March 31

Indi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at the Spring 2021 Oncology Investor Conference on March 31. The conference is being held virtually from March 29 - April 2, 2021.

Biocom 2021 to Include Presentation by Indi Molecular CEO Albert A. Luderer

Indi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at Biocom’s 11th Annual Global Life Science Partnering Conference held virtually February 23-25, 2021. His presentation will be available on-demand to conference participants.

Indi Molecular CEO Albert A. Luderer to Present at BIO 2021 CEO & Investor Digital Conference

Indi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at BIO’s 2021 CEO & Investor Digital Conference held virtually February 16-18, 2021. His presentation will be available on-demand to conference participants.

Chemical Science Publishes Article on Protein-Catalyzed Capture Agents that Combat Antibiotic Resistant Bacteria

CULVER CITY, CA, March 3, 2020 - Indi Molecular today announced that Chemical Science has published an article on a combined computational and synthetic approach for developing antibiotics against drug resistant pathogens called antibody-recruiting protein-catalyzed capture agents (AR-PCCs).
Show more

Indi Molecular Frequently Asked Questions

  • When was Indi Molecular founded?

    Indi Molecular was founded in 2013.

  • Who are Indi Molecular key executives?

    Indi Molecular's key executives are Albert A. Luderer, Heather Agnew and Michael T. Klimas.

  • How many employees does Indi Molecular have?

    Indi Molecular has 30 employees.

  • Who are Indi Molecular competitors?

    Competitors of Indi Molecular include Gravity Diagnostics, SD Biosensor and Source Bioscience.

  • Where is Indi Molecular headquarters?

    Indi Molecular headquarters is located at 6162 Bristol Pkwy, Culver City.

  • Where are Indi Molecular offices?

    Indi Molecular has an office in Culver City.

  • How many offices does Indi Molecular have?

    Indi Molecular has 1 office.